Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma
- PMID: 29128421
- DOI: 10.1016/j.urolonc.2017.09.030
Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma
Abstract
Purpose: Cytoreductive radical nephrectomy (cRN) improves survival in select patients with metastatic renal cell carcinoma (mRCC). It is unclear, however, whether cytoreductive partial nephrectomy (cPN) compromises oncologic efficacy. We evaluated trends in utilization of cPN and compared overall survival (OS) in patients who underwent cRN or cPN for mRCC.
Materials and methods: We queried the National Cancer Database from 2006 to 2013 and identified patients who underwent cPN and cRN for mRCC. We analyzed rates of cPN over time. Logistic regression identified predictors of cPN. We matched patients based on propensity score for treatment. We used matched Kaplan-Meier survival analyses to compare OS, stratified by tumor size. We used multivariable Cox proportional hazards models to determine the effect of cPN and cRN on OS.
Results: A total of 10,144 patients met inclusion criteria, with 9,764 (96.2%) undergoing cRN and 381 (3.8%) undergoing cPN. Rates of cPN increased over time from 1.8% to 4.3% over the study period. Treatment at an academic/research facility, papillary and chromophobe histology, and more recent year of treatment were associated with increased odds of cPN. In a matched survival analysis, cPN was associated with improved OS compared with cRN (log rank, P = 0.001). This effect was limited to primary tumors<4cm. In a propensity-score adjusted multivariable Cox model, cPN was associated with improved OS (hazard ratio = 0.81; 95% CI: 0.71-0.93; P = 0.002).
Conclusions: The use of cPN in patients with mRCC is increasing. cPN is associated with improved OS in patients with mRCC, although this effect is limited to patients with primary tumors<4cm.
Keywords: Cytoreduction surgical procedures; Neoplasm metastasis; Renal cell carcinoma; Survival analysis; outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2. Urol Oncol. 2018. PMID: 29103965
-
[Cytoreductive Partial Nephrectomy versus Cytoreductive Radical Nephrectomy for Locally T 1 Stage Metastatic Renal Rell Carcinoma (mRCC)].Sichuan Da Xue Xue Bao Yi Xue Ban. 2020 Jul;51(4):546-551. doi: 10.12182/20200760204. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 32691565 Chinese.
-
The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma.Clin Interv Aging. 2020 Mar 20;15:431-439. doi: 10.2147/CIA.S243902. eCollection 2020. Clin Interv Aging. 2020. PMID: 32256058 Free PMC article.
-
Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma.Urologia. 2022 May;89(2):160-166. doi: 10.1177/03915603221092096. Epub 2022 Apr 15. Urologia. 2022. PMID: 35422178
-
Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.Am Soc Clin Oncol Educ Book. 2019 Jan;39:276-283. doi: 10.1200/EDBK_237453. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099657 Review.
Cited by
-
Cytoreductive nephrectomy in metastatic renal cell carcinoma.Cochrane Database Syst Rev. 2024 Jun 7;6(6):CD013773. doi: 10.1002/14651858.CD013773.pub2. Cochrane Database Syst Rev. 2024. PMID: 38847285 Free PMC article.
-
Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1-2M1 renal cell carcinoma.Transl Cancer Res. 2023 Feb 28;12(2):301-309. doi: 10.21037/tcr-22-1389. Epub 2023 Jan 29. Transl Cancer Res. 2023. PMID: 36915574 Free PMC article.
-
Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.IJU Case Rep. 2022 Mar 25;5(3):168-171. doi: 10.1002/iju5.12427. eCollection 2022 May. IJU Case Rep. 2022. PMID: 35509785 Free PMC article.
-
The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma.Cancers (Basel). 2023 Jul 29;15(15):3855. doi: 10.3390/cancers15153855. Cancers (Basel). 2023. PMID: 37568671 Free PMC article. Review.
-
Renal Cell Carcinoma Presenting as an Isolated Eyelid Metastasis.J Endourol Case Rep. 2020 Dec 29;6(4):322-324. doi: 10.1089/cren.2020.0107. eCollection 2020. J Endourol Case Rep. 2020. PMID: 33457664 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous